Investors & Media

Press Releases

Date Title View
Toggle Summary SAGE Therapeutics Announces Closing of Initial Public Offering
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- SAGE Therapeutics , a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public
View HTML
Toggle Summary SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus
Designation Underscores Unmet Medical Need for Life-Threatening Seizure Condition CAMBRIDGE, Mass. --(BUSINESS WIRE)-- SAGE Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, announced today
View HTML
Toggle Summary SAGE Therapeutics Announces Full Exercise of Over-Allotment Option
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- SAGE Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that the underwriters of its initial public offering (IPO) exercised in full their
View HTML
Toggle Summary SAGE Therapeutics Announces Pricing of Initial Public Offering View HTML
Toggle Summary SAGE Therapeutics Appoints James M. Frates to the Company's Board of Directors View HTML
Toggle Summary SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data at Epilepsy Pipeline Conference View HTML
Toggle Summary SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer View HTML
Toggle Summary SAGE Therapeutics Receives U.S. Orphan Drug Designation for Lead Compound SAGE-547 to Treat Status Epilepticus
SAGE Therapeutics Receives U.S. Orphan Drug Designation for Lead Compound SAGE-547 to Treat Status Epilepticus
View HTML
Toggle Summary SAGE Therapeutics Appoints Howard H. Pien to the Company's Board of Directors
SAGE Therapeutics Appoints Howard H. Pien to the Company's Board of Directors
View HTML
Toggle Summary SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus
SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus
View HTML